Neurology

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease.  The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment.  The UQ team was led by Professor Trent Woodruff and Dr Eduardo […]

Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J Mark Treherne, Dr Jenny Barnett and Dr Paula Moran.  Increasingly, digital biomarkers are becoming more effectively used in the discovery and development of drugs that act in the central nervous system. However, unlike […]

Biopharmaceutical company TikoMed has announced two new appointments to its Board of Directors as the company focuses on its ILB drug programme. TikoMed has appointed Tara Heitner and Pete Zorn to its Board of Directors. Tara Heitner has more than 15 years of experience in the biopharmaceutical industry and has been involved in the development […]

Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.   Cerevance will receive an upfront payment of $25 million from Merck (MSD) and could receive development and commercial milestone payments of up to $1.1 billion, in addition to potential royalties on […]

Clinical stage biotech company Oxeia Biopharmaceuticals has announced interim results from a Phase II trial investigating its treatment for concussion.  Oxeia’s OXE103 treatment is targeting concussion in a bid to address underlying neuro-metabolic dysfunction and axonal injury. The company has now completed an interim analysis of its ongoing Phase 2 clinical trial of OXE103 at […]

News round-up by DDW’s Reece Armstrong for 1-5 August Research paves way for easier brain tumour diagnosis New research could pave the way to the earlier diagnosis of brain tumours through the development of a simple blood test for glioblastomas. IFC invests $30 million to improve healthcare in Latin America The International Finance Corporation (IFC) […]

New research could pave the way to the earlier diagnosis of brain tumours through the development of a simple blood test for glioblastomas.  Researchers from the University of Bristol in the UK, developed mathematical models to assess the current use of biomarkers in the detection of glioblastomas and how this diagnostic approach can be improved.  […]

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases.   The agreement will see the companies combining their expertise and capabilities in neuroscience to discover and develop small molecules that modulate G protein-coupled receptor (GPCR) targets that are associated with neurological […]

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma.  The phase I physician-sponsored clinical trial will take place at City of Hope and will address the safety […]

Two start-ups have won a competition organised by EIT Health and pharmaceutical company Biogen which aimed at identifying solutions for Alzheimer’s disease.   French start-up Five Lives and Dutch start-up Neurocase were respectively placed first and second in the ‘neurotechprize’ competition. The winners were announced during a ceremony at the MedtecLIVE conference and will now receive […]

Ferrer, a pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has enrolled the first patient in its Amyotrophic Lateral Sclerosis (ALS) Deceleration with ORal Edaravone (ADORE), FNP122 Phase III clinical trial.   The trial   The trial will enrol about 300 patients across European countries and it will evaluate the efficacy, survival and safety of FNP122 as an oral […]